文献速递临床试验与 GCP流行病学与生物统计

裸盖菇素治疗抑郁症状的疗效:系统综述与Meta分析

Efficacy of psilocybin for treating symptoms of depression: systematic review and meta-analysis.
PubMed 文献 · BMJ · 2024-05-01

该系统综述与Meta分析纳入9项随机试验,对其中7项研究的436名参与者进行Meta分析,比较裸盖菇素与安慰剂或非精神活性药物对抑郁症状评分的改变。结果显示裸盖菇素组抑郁评分改善显著优于对照(Hedges g=0.66,95%CI 0.46至0.86,P<0.001),继发性抑郁、自评量表评估及既往使用致幻剂与更大改善相关,证据确定性为中等。

要点

  • 裸盖菇素较对照显著改善抑郁评分(Hedges g=0.66,95%CI 0.46至0.86,P<0.001)。
  • 继发性抑郁者效应量Hedges g=0.88(95%CI 0.42至1.33),自评量表评估者亦为0.88(0.42至1.33)。
  • 所有研究存在中等偏倚风险,但基线变化指标异质性低且小研究偏倚检验无统计学显著,证据确定性中等。

核心结论

  • 裸盖菇素作为抗抑郁药与安慰剂或非精神活性药物相比,在改变抑郁评分方面显示出显著获益(Hedges g=0.66,95%CI 0.46至0.86,P<0.001)。
  • 继发性抑郁、使用自评抑郁量表评估以及年龄较大和既往使用致幻剂与更大的症状改善相关。
  • 需要进一步研究以阐明期望效应、调节因素和治疗实施对裸盖菇素抗抑郁疗效的影响。

研究设计与样本

  • 系统综述与Meta分析,检索5个已发表文献电子数据库、4个未发表及国际文献数据库,并手工检索参考文献、会议论文集和摘要。
  • 纳入裸盖菇素作为单一治疗用于有临床显著抑郁症状的成人的随机试验,症状改变用验证过的临床医生评定或自评量表测量。
  • Meta分析纳入9项研究中7项研究的436名参与者(228名女性),平均年龄36-60岁。
  • 使用随机效应Meta分析模型合成数据,亚组分析和元回归探讨异质性和协变量效应,Hedges g作为效应量。
  • 使用Cochrane偏倚风险2工具评估研究质量,GRADE指南评估证据质量。

主要发现

  • 与对照治疗相比,裸盖菇素组抑郁评分改变显著更优(Hedges g=0.66,95%CI 0.46至0.86,P<0.001)。
  • 继发性抑郁者效应量Hedges g=0.88(95%CI 0.42至1.33),自评抑郁量表(如贝克抑郁量表)评估者效应量0.88(0.42至1.33)。
  • 年龄较大和既往使用致幻剂的元回归系数分别为0.13(95%CI 0.02至0.23)和6.00(95%CI 2.48至9.53),与更大症状改善相关。
  • 所有研究存在中等偏倚风险,但基线变化指标异质性低且小研究偏倚风险无统计学显著,证据确定性评级为中等。

关键数值与推荐

  • 纳入标准:裸盖菇素作为单一治疗用于有临床显著抑郁症状的成人的随机试验,症状改变用验证过的临床医生评定或自评量表测量。
  • 若指导性心理治疗在实验组和对照组均存在,则包含此类研究;参与者无论是否有合并症(如癌症)均符合条件。
  • 主要效应量:Hedges g=0.66(95%CI 0.46至0.86,P<0.001),比较裸盖菇素与对照治疗对抑郁评分改变的影响。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 所有研究存在中等偏倚风险。
  • 需要进一步研究以阐明期望效应、调节因素和治疗实施对裸盖菇素抗抑郁疗效的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine the efficacy of psilocybin as an antidepressant compared with placebo or non-psychoactive drugs. DESIGN: Systematic review and meta-analysis. DATA SOURCES: Five electronic databases of published literature (Cochrane Central Register of Controlled Trials, Medline, Embase, Science Citation Index and Conference Proceedings Citation Index, and PsycInfo) and four databases of unpublished and international literature (ClinicalTrials.gov, WHO International Clinical Trials Registry Platform, ProQuest Dissertations and Theses Global, and PsycEXTRA), and handsearching of reference lists, conference proceedings, and abstracts. DATA SYNTHESIS AND STUDY QUALITY: Information on potential treatment effect moderators was extracted, including depression type (primary or secondary), previous use of psychedelics, psilocybin dosage, type of outcome measure (clinician rated or self-reported), and personal characteristics (eg, age, sex). Data were synthesised using a random effects meta-analysis model, and observed heterogeneity and the effect of covariates were investigated with subgroup analyses and metaregression. Hedges’ g was used as a measure of treatment effect size, to account for small sample effects and substantial differences between the included studies’ sample sizes. Study quality was appraised using Cochrane’s Risk of Bias 2 tool, and the quality of the aggregated evidence was evaluated using GRADE guidelines. ELIGIBILITY CRITERIA: Randomised trials in which psilocybin was administered as a standalone treatment for adults with clinically significant symptoms of depression and change in symptoms was measured using a validated clinician rated or self-report scale. Studies with directive psychotherapy were included if the psychotherapeutic component was present in both experimental and control conditions. Participants with depression regardless of comorbidities (eg, cancer) were eligible. RESULTS: Meta-analysis on 436 participants (228 female participants), average age 36-60 years, from seven of the nine included studies showed a significant benefit of psilocybin (Hedges’ g=0.66, 95% confidence interval (CI) 0.46 to 0.86, P<0.001) on change in depression scores compared with comparator treatment. Exploratory subgroup analyses and metaregressions indicated that having secondary depression (Hedges’ g=0.88, 95% CI 0.42 to 1.33), being assessed with self-report depression scales such as the Beck depression inventory (0.88, 0.42 to 1.33), and older age and previous use of psychedelics (metaregression coefficient 0.13, 95% CI 0.02 to 0.23 and 6.00, 2.48 to 9.53, respectively) were correlated with greater improvements in symptoms. All studies had a moderate risk of bias, but the change from baseline metric was associated with low heterogeneity and a statistically non-significant risk of small study bias, resulting in a moderate certainty of evidence rating. CONCLUSION: Treatment effects of psilocybin were significantly larger among patients with secondary depression, when self-report scales were used to measure symptoms of depression, and when participants had previously used psychedelics. Further research is thus required to delineate the influence of expectancy effects, moderating factors, and treatment delivery on the efficacy of psilocybin as an antidepressant. SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42023388065.

来源:BMJ,查看原文。版权归原作者所有。

引用

  1. Metaxa AM, Clarke M. Efficacy of psilocybin for treating symptoms of depression: systematic review and meta-analysis. BMJ. 2024. PMID: 38692686. doi:10.1136/bmj-2023-078084

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。